Busulfan

CHEMBL820 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
246.3 g/mol
LogP
-0.5
Phase
4

An alkylating agent used to condition patients for bone marrow transplantation by destroying the existing bone marrow and suppressing the immune system to allow engraftment. It is also used in the treatment of chronic myelogenous leukemia. Major side effects include severe bone marrow suppression, pulmonary toxicity, and risk of secondary cancers.

分子量

246.3000 g/mol

LogP

-0.50

TPSA

104.00 Ų

Lipinski 五规则

符合

治疗领域

作用机制

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

Molecular Formula

C6H14O6S2

HBD / HBA

- / 6

可旋转键数

7

重原子数

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

An alkylating agent used to condition patients for bone marrow transplantation by destroying the existing bone marrow and suppressing the immune system to allow engraftment. It is also used in the treatment of chronic myelogenous leukemia. Major side effects include severe bone marrow suppression, pulmonary toxicity, and risk of secondary cancers.

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

Yes, Busulfan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL820. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2478. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.